Investing.com - Financial Markets Worldwide

Aytu BioScience Inc (AYTU)

NASDAQ
Currency in USD
1.110
+0.010(+0.91%)
Closed·
After Hours
1.060-0.050(-4.505%)
·
AYTU Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Unlock Value
Day's Range
1.0501.110
52 wk Range
0.9503.448
Key Statistics
Edit
Prev. Close
1.05
Open
1.06
Day's Range
1.05-1.11
52 wk Range
0.95-3.448
Volume
30.95K
Average Vol. (3m)
34.38K
1-Year Change
-62.5%
Book Value / Share
5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AYTU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Buy
Analysts Sentiment
Buy
Price Target
8.000
Upside
+620.72%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 12
Net income is expected to grow this year
Unlock InvestingPro

Aytu BioScience Inc News & Analysis

Show more

Aytu BioScience Inc Company Profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
102
Market
United States

Aytu BioScience Inc Earnings Call Summary for Q2/2025

  • Q2 2025 net revenue fell to $16.2M from $18.7M YoY; ADHD portfolio down 17%, pediatric segment grew
  • Net income of $800K ($0.13/share); 37% reduction in G&A expenses over 2 years; cash balance slightly up at $20.4M
  • Targeting $16-17M quarterly ADHD revenue; exploring CNS/psychiatry and pediatrics opportunities for growth
  • CEO expects revenue and adjusted EBITDA growth; focus on profitable prescription business and cost management
  • Analysts maintain Buy consensus with $8 price target; stock down 16.5% in past week despite undervalued status
Last Updated: 02/13/2025, 02:36 PM
Read Full Transcript

Compare AYTU to Peers and Sector

Metrics to compare
AYTU
Peers
Sector
Relationship
P/E Ratio
−0.9x−0.2x−0.5x
PEG Ratio
−0.020.000.00
Price / Book
0.2x1.3x2.6x
Price / LTM Sales
0.1x2.4x2.9x
Upside (Analyst Target)
-114.6%58.9%
Fair Value Upside
Unlock6.6%8.0%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8.000
(+620.72% Upside)

Earnings

Latest Release
Feb 12, 2025
EPS / Forecast
-0.28 / -0.25
Revenue / Forecast
16.22M / 21.75M
EPS Revisions
a
a
Unlock
Last 90 days

People Also Watch

Scorpius Holdings
0.0450
SCPX
+4.65%
LM Funding America
1.650
LMFA
+15.38%
Yatra Online
0.693
YTRA
+0.58%
Kiora Pharmaceuticals
3.200
KPRX
-1.84%
High Roller Tech
3.07
ROLR
+5.86%

FAQ

What Is the Aytu BioScience (AYTU) Stock Price Today?

The Aytu BioScience stock price today is 1.11

What Stock Exchange Does Aytu BioScience Trade On?

Aytu BioScience is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Aytu BioScience?

The stock symbol for Aytu BioScience is "AYTU."

What Is the Aytu BioScience Market Cap?

As of today, Aytu BioScience market cap is 6.76M.

What is Aytu BioScience Earnings Per Share?

The Aytu BioScience EPS is -1.24.

From a Technical Analysis Perspective, Is AYTU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.